

March 31, 2026

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

email: ir@ppmx.com

Notice Regarding Full-Year Earnings Forecast for the FY2026/3

Perseus Proteomics Inc. (the “Company”) hereby announces that it has determined its financial forecasts for the fiscal year ending March 31, 2026, which had previously been undetermined, as follows.

1. Non-consolidated financial results forecasts for the FY2026/3

	Net sales	Operating income	Ordinary income	Profit	Earnings per share
Previously announced forecasts (A)	-	-	-	-	-
Revised forecasts (B)	135	(772)	(707)	(758)	(50.88)
Change (B-A)	-	-	-	-	-
Change (%)	-	-	-	-	-
(Reference) Actual Non-consolidated results for FY2025/3	120	(826)	(829)	(904)	(63.41)

Unit: million yen, except net income per share (yen)

2. Reasons for disclosure

The Company has continued activities aimed at out-licensing PPMX-T002 and PPMX-T003. However, because there were many uncertain factors affecting business performance, it had been difficult to reasonably estimate the impact on net sales and operating expenses for the fiscal year ending March 31, 2026, and therefore the Company had not previously disclosed its financial forecasts.

Although out-licensing activities for these pipeline products are still ongoing, no out-licensing has been achieved to date. Accordingly, the Company is hereby announcing its full-year financial forecasts based on information currently available and forecasts made at this point in time.

With respect to expenses, research and development expenses are expected to be 604 million yen, other administrative expenses are expected to be 287 million yen, and selling, general and administrative expenses are expected to be 892 million yen.

3. Future initiatives

The Company will continue out-licensing activities for both pipeline products.

Note: Actual results may differ from these forecasts due to various factors.

END